Cementless Knee Replacement for Osteoarthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
The primary objective of this study is to examine the change from pre-operative baseline to two year postoperative functional performance improvement for the ATTUNE primary, cementless TKA RP system as measured with the KOOS questionnaire (KOOS-ADL sub-score). This will be carried out for two configurations: cruciate retaining rotating platform (ATTUNE Cementless CR RP) and posterior stabilized rotating platform (ATTUNE Cementless PS RP).
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you are taking prescription medications for a muscular disorder that limits mobility, you may not be eligible to participate.
Is cementless knee replacement generally safe for humans?
Cementless knee replacements have been studied for safety, showing some complications like higher revision rates compared to cemented ones, but also demonstrating good long-term outcomes in certain designs. Some studies found no significant increase in complications compared to cemented options, suggesting they can be safe for treating knee osteoarthritis.12345
How does cementless total knee arthroplasty differ from other treatments for osteoarthritis?
Cementless total knee arthroplasty is unique because it avoids using cement to fix the knee implant, aiming for a natural bond between the bone and implant. This method is particularly appealing for younger patients with good bone quality, as it preserves bone stock and reduces the risk of cement-related issues, although it may have a higher revision rate compared to cemented options.13678
What data supports the effectiveness of the treatment Cementless Total Knee Arthroplasty for osteoarthritis?
Research shows that cementless knee replacements, like the Miller-Galante type, improve pain, movement, and walking ability significantly over 2 to 5 years, with no signs of loosening in the uncemented components. Additionally, a study found similar long-term survival rates for cementless and cemented knee replacements, suggesting that cementless options can be effective.1491011
Who Is on the Research Team?
Sukhjeet Kaur
Principal Investigator
Sponsor GmbH
Are You a Good Fit for This Trial?
This trial is for men and women aged 22-80 who are not bedridden, can consent to the study, understand procedures, complete questionnaires in English or translations provided, diagnosed with non-inflammatory degenerative joint disease (NIDJD), and suitable for cementless knee replacement. Exclusions include recent participation in other trials, litigation involvement, inflammatory arthritis conditions, life expectancy under five years, pregnancy/lactation status among others.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Surgery and Initial Recovery
Participants undergo the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty and initial recovery
Post-operative Assessment
Participants are assessed for post-operative outcomes using various patient-reported measures and radiographic evaluations
Long-term Follow-up
Participants are monitored for long-term outcomes, including survivorship and adverse events
What Are the Treatments Tested in This Trial?
Interventions
- Cementless Total Knee Arthroplasty
Cementless Total Knee Arthroplasty is already approved in United States, European Union for the following indications:
- Severe knee damage due to arthritis or injury
- Significant knee pain
- Younger patients with good bone quality
- Severe knee damage due to arthritis or injury
- Significant knee pain
- Younger patients with good bone quality
Find a Clinic Near You
Who Is Running the Clinical Trial?
DePuy Orthopaedics
Lead Sponsor
Massimo Calafiore
DePuy Orthopaedics
Chief Executive Officer since 2023
MBA from Harvard Business School
Dr. Michael Stein
DePuy Orthopaedics
Chief Medical Officer since 2023
MD from University of Michigan